Upharmacia December 2017
PHARMA MARKET NEWS
Farmak Expects Increase of Retail
Sales by 18 % in
2018
Ukraine’ s leading pharmaceutical company Farmak expects the sales of its drugs to rise by 18 % y-o-y in UAH in 2018, the company’ s Marketing Director Susanna Halilova stated. Herewith, the forecast on sales in volumes is unclear.
Farmak anticipates the medical reform to have impact on pharmaceutical market with regard to the changes in the sales structure of certain groups of drugs.
According to the forecast of Business Credit analytical company, the retail sales of Ukrainian drugs may increase 4 % in volumes and 10 % in values.
Yuria-Pharm may Supply
TB Drugs to Brazil
Ukrainian company Yuria-Pharm considers the possibility to supply its antitubercular drugs to Brazil, the company’ s Director Dmytro Derkach said. Currently, the company is waiting for the results of the inspection conducted by the Brazilian regulatory body( ANVISA) in Nov.
“ Brazil is interested in Yuria-Pharm’ s production, in particular, in its antitubercular drugs,” Mr. Derkach stated.
In 2018, Yuria-Pharm plans to continue implementing production of new drugs and
entering new external markets. Now, the company’ s products are represented in 25 countries.
In 9M2017, Yuria-Pharm was a # 1 supplier on the Ukrainian hospital drug market with 10 % market share. On the retail drug market, the company held 10th position.
Biofarma to Open a Blood Plasma Fractionation Plant in 2018
Ukrainian producer of blood preparations Biofarma plans to launch a blood plasma fractionation plant in Jul 2018. The plant’ s construction will cost USD 35 mio. Its capacity is to amount 500 tons of blood plasma.
“ We have an ambition to become a TOP-7 producer of blood plasma in the world”, Biofarma’ s President Konstantin Efimenko stated.
Biofarma produces more than 20 immunobiological preparations from donor blood obtained according to technology of recombinant DNA and probiotics. In 2014, the company constructed its new plant in Bila Tserkva, investing about USD 42 mio.
Interchem Launched new
API Production Complex
Ukrainian company Interchem launched a new production complex for the production of Active Pharmaceutical Ingredients( API) at its plant in Odessa.
Completion of the complex construction has become the last phase within an investment project worth EUR 50 mio, which had been started in 2012. About EUR 9 mio were invested in the construction of the complex.
Interchem also implemented a new drug labeling system used to automatically track the movement of drugs from the manufacturer to the end user or patient. The system uses two-dimensional codes of the GS1 ECC200 standard and was developed with recommendations of the European Federation of Pharmaceutical Industries and associations( EFPIA).
“ Counterfeit drugs are a serious problem in Ukraine”, the Director of Interchem Anatoliy Reder said.“ As a single company in Ukraine, which implemented such system, Interchem participates in the pilot project of the State Service on Drug Control, aimed to addressing the problem through tracking the drugs turnover.”
Interchem is a full-cycle enterprise, which produces above 100 forms of drugs. In 2016, Interchem was a 25th company on Ukrainian drug market by sales in values. In Dec, the company celebrated its 25th anniversary.
Indian Companies Plan to Increase Exports to Ukraine
to USD 300 mio in
2018
Indian Pharmaceutical Manufacturers Association( IPMA) stated that in 2016 exports to
6 www. upharma-c. com